Year-end Sale % OFF 
Abstract
How does a 1.5-Fold Increase in Gene Dosage in Chromosome 21 Causes the Pleiotropic Phenotypes in Down Syndrome?
Highlights
Amplifying the effects of their 1.5-fold gene dosage in HSA21
The nuclear factor one (NFI)-regulated developmental switch program controls the expression of several groups of genes during the postnatal development in the cerebellum
A recent genome-wide analysis of DYRK1A-associated loci reveals that the kinase is recruited preferentially to the promoters of genes actively transcribed by RNA polymerase II (RNAPII), which is functionally associated with translation, RNA processing, and the cell cycle
Summary
Amplifying the effects of their 1.5-fold gene dosage in HSA21. The cooperative actions of DYRK1A and DSCR1 have been shown to suppress NFAT activity in neural progenitors, leading to a delay in neuronal differentiation and the alteration of their laminar fate [9]. The NFAT family of transcription factors could function to directly promote gene expression via binding the consensus sequence at target gene promoter region.
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Down Syndrome & Chromosome Abnormalities
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
